Seasonal and climatic influence on respiratory infections in children with cystic fibrosis

被引:0
作者
Mesinele, Julie [1 ,2 ]
Ruffin, Manon [1 ]
Guillot, Loic [1 ]
Boelle, Pierre-Yves [3 ]
Corvol, Harriet [1 ,4 ]
机构
[1] Sorbonne Univ, Ctr Rech St Antoine CRSA, Inserm U938, F-75012 Paris, France
[2] Inovarion, F-75005 Paris, France
[3] Sorbonne Univ, Hop St Antoine, Assistance Publ Hop Paris AP HP, Inst Pierre Louis Epidemiol & Sante Publ iPLESP,In, F-75012 Paris, France
[4] Sorbonne Univ, Hop Trousseau, AP HP, Serv Pneumol Pediat, F-75012 Paris, France
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Environmental factors; Seasonality; Climate; Cystic fibrosis; <italic>Pseudomonas aeruginosa</italic>; <italic>Staphylococcus aureus</italic>; PSEUDOMONAS-AERUGINOSA ACQUISITION; YOUNG-CHILDREN; AIR-POLLUTION; UNITED-STATES; RISK;
D O I
10.1038/s41598-024-77253-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pseudomonas aeruginosa (Pa) and Methicillin susceptible Staphylococcus aureus (MSSA) are the predominant bacteria found in the airways of people with cystic fibrosis (pwCF), significantly contributing to lung disease progression. While various factors influencing the initial acquisition (IA) of these pathogens are known, the impact of environmental conditions remains understudied. This epidemiological study assessed the risk of MSSA and Pa initial acquisitions in relation to seasonality and climatic zones among 1,184 French pwCF under 18 years old. The age at IA for Pa (Pa-IA) and MSSA (MSSA-IA) was estimated using the Kaplan-Meier method. Seasonality and climatic zones were analysed as risk factors using time-varying Cox regression models. The median age at MSSA-IA was notably earlier (2.0 years) than that at Pa-IA (5.1 years). MSSA-IA occurred increasingly younger in more recent birth cohorts, while the age at Pa-IA remained stable over time. The risk of Pa-IA was consistently higher in all seasons compared with spring, peaking in autumn (HR = 1.53), irrespective of climatic zones. In Oceanic and Continental climates, the highest risk for MSSA-IA was in winter (HRs = 1.45 and 1.20 respectively). In the Mediterranean climate, the risk of MSSA-IA was lower in winter compared to spring (HRs = 0.68 and 0.61 respectively), and the median age at MSSA-IA later than for Pa-IA. This study demonstrates that seasonality and meteorological factors may influence acquisition of MSSA and Pa in pwCF. These findings suggest that environmental factors play a role in pathogen acquisition dynamics in CF and could inform the development of preventive strategies.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis
    Metz, Jakob
    Eber, Ernst
    Resch, Bernhard
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (06) : 545 - 548
  • [32] The role of rhinovirus infections in young children with cystic fibrosis
    Loughlin, D. W. O.
    Coughlan, S.
    De Gascun, C. F.
    McNally, P.
    Cox, D. W.
    JOURNAL OF CLINICAL VIROLOGY, 2020, 129
  • [33] Respiratory sleep disturbance in children and adolescents with cystic fibrosis
    Silva, A. M.
    Descalco, A.
    Salgueiro, M.
    Pereira, L.
    Barreto, C.
    Bandeira, T.
    Ferreira, R.
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2016, 22 (04) : 202 - 208
  • [34] Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics
    Ballmann, Manfred
    Smyth, Alan
    Geller, David E.
    RESPIRATORY MEDICINE, 2011, 105 : S2 - S8
  • [35] Nontuberculous Mycobacterial Infections in Cystic Fibrosis
    Martiniano, Stacey L.
    Nick, Jerry A.
    Daley, Charles L.
    CLINICS IN CHEST MEDICINE, 2022, 43 (04) : 697 - 716
  • [36] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    Mckoy, Naomi A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
  • [37] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    Mckoy, Naomi A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
  • [38] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
  • [39] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
  • [40] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian
    Mckoy, Naomi
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (02):